Thomas R Arkell1,2,3,4, Frederick Vinckenbosch4, Richard C Kevin1,2,5, Eef L Theunissen4, Iain S McGregor1,2,5, Johannes G Ramaekers4. 1. Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia. 2. Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia. 3. Central Clinical School, Faculty of Medicine, The University of Sydney, Sydney, New South Wales, Australia. 4. Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands. 5. Faculty of Science, The University of Sydney School of Psychology, Sydney, New South Wales, Australia.
Abstract
Importance: Cannabis use has been associated with increased crash risk, but the effect of cannabidiol (CBD) on driving is unclear. Objective: To determine the driving impairment caused by vaporized cannabis containing Δ9-tetrahydrocannabinol (THC) and CBD. Design, Setting, and Participants: A double-blind, within-participants, randomized clinical trial was conducted at the Faculty of Psychology and Neuroscience at Maastricht University in the Netherlands between May 20, 2019, and March 27, 2020. Participants (N = 26) were healthy occasional users of cannabis. Interventions: Participants vaporized THC-dominant, CBD-dominant, THC/CBD-equivalent, and placebo cannabis. THC and CBD doses were 13.75 mg. Order of conditions was randomized and balanced. Main Outcomes and Measures: The primary end point was standard deviation of lateral position (SDLP; a measure of lane weaving) during 100 km, on-road driving tests that commenced at 40 minutes and 240 minutes after cannabis consumption. At a calibrated blood alcohol concentration (BAC) of 0.02%, SDLP was increased relative to placebo by 1.12 cm, and at a calibrated BAC of 0.05%, SDLP was increased relative to placebo by 2.4 cm. Results: Among 26 randomized participants (mean [SD] age, 23.2 [2.6] years; 16 women), 22 (85%) completed all 8 driving tests. At 40 to 100 minutes following consumption, the SDLP was 18.21 cm with CBD-dominant cannabis, 20.59 cm with THC-dominant cannabis, 21.09 cm with THC/CBD-equivalent cannabis, and 18.28 cm with placebo cannabis. SDLP was significantly increased by THC-dominant cannabis (+2.33 cm [95% CI, 0.80 to 3.86]; P < .001) and THC/CBD-equivalent cannabis (+2.83 cm [95% CI, 1.28 to 4.39]; P < .001) but not CBD-dominant cannabis (-0.05 cm [95% CI, -1.49 to 1.39]; P > .99), relative to placebo. At 240 to 300 minutes following consumption, the SDLP was 19.03 cm with CBD-dominant cannabis, 19.88 cm with THC-dominant cannabis, 20.59 cm with THC/CBD-equivalent cannabis, and 19.37 cm with placebo cannabis. The SDLP did not differ significantly in the CBD (-0.34 cm [95% CI, -1.77 to 1.10]; P > .99), THC (0.51 cm [95% CI, -1.01 to 2.02]; P > .99) or THC/CBD (1.22 cm [95% CI, -0.29 to 2.72]; P = .20) conditions, relative to placebo. Out of 188 test drives, 16 (8.5%) were terminated due to safety concerns. Conclusions and Relevance: In a crossover clinical trial that assessed driving performance during on-road driving tests, the SDLP following vaporized THC-dominant and THC/CBD-equivalent cannabis compared with placebo was significantly greater at 40 to 100 minutes but not 240 to 300 minutes after vaporization; there were no significant differences between CBD-dominant cannabis and placebo. However, the effect size for CBD-dominant cannabis may not have excluded clinically important impairment, and the doses tested may not represent common usage. Trial Registration: EU Clinical Trials Register: 2018-003945-40.
RCT Entities:
Importance: Cannabis use has been associated with increased crash risk, but the effect of cannabidiol (CBD) on driving is unclear. Objective: To determine the driving impairment caused by vaporized cannabis containing Δ9-tetrahydrocannabinol (THC) and CBD. Design, Setting, and Participants: A double-blind, within-participants, randomized clinical trial was conducted at the Faculty of Psychology and Neuroscience at Maastricht University in the Netherlands between May 20, 2019, and March 27, 2020. Participants (N = 26) were healthy occasional users of cannabis. Interventions: Participants vaporized THC-dominant, CBD-dominant, THC/CBD-equivalent, and placebo cannabis. THC and CBD doses were 13.75 mg. Order of conditions was randomized and balanced. Main Outcomes and Measures: The primary end point was standard deviation of lateral position (SDLP; a measure of lane weaving) during 100 km, on-road driving tests that commenced at 40 minutes and 240 minutes after cannabis consumption. At a calibrated blood alcohol concentration (BAC) of 0.02%, SDLP was increased relative to placebo by 1.12 cm, and at a calibrated BAC of 0.05%, SDLP was increased relative to placebo by 2.4 cm. Results: Among 26 randomized participants (mean [SD] age, 23.2 [2.6] years; 16 women), 22 (85%) completed all 8 driving tests. At 40 to 100 minutes following consumption, the SDLP was 18.21 cm with CBD-dominant cannabis, 20.59 cm with THC-dominant cannabis, 21.09 cm with THC/CBD-equivalent cannabis, and 18.28 cm with placebo cannabis. SDLP was significantly increased by THC-dominant cannabis (+2.33 cm [95% CI, 0.80 to 3.86]; P < .001) and THC/CBD-equivalent cannabis (+2.83 cm [95% CI, 1.28 to 4.39]; P < .001) but not CBD-dominant cannabis (-0.05 cm [95% CI, -1.49 to 1.39]; P > .99), relative to placebo. At 240 to 300 minutes following consumption, the SDLP was 19.03 cm with CBD-dominant cannabis, 19.88 cm with THC-dominant cannabis, 20.59 cm with THC/CBD-equivalent cannabis, and 19.37 cm with placebo cannabis. The SDLP did not differ significantly in the CBD (-0.34 cm [95% CI, -1.77 to 1.10]; P > .99), THC (0.51 cm [95% CI, -1.01 to 2.02]; P > .99) or THC/CBD (1.22 cm [95% CI, -0.29 to 2.72]; P = .20) conditions, relative to placebo. Out of 188 test drives, 16 (8.5%) were terminated due to safety concerns. Conclusions and Relevance: In a crossover clinical trial that assessed driving performance during on-road driving tests, the SDLP following vaporized THC-dominant and THC/CBD-equivalent cannabis compared with placebo was significantly greater at 40 to 100 minutes but not 240 to 300 minutes after vaporization; there were no significant differences between CBD-dominant cannabis and placebo. However, the effect size for CBD-dominant cannabis may not have excluded clinically important impairment, and the doses tested may not represent common usage. Trial Registration: EU Clinical Trials Register: 2018-003945-40.
Authors: J G Ramaekers; M R Moeller; P van Ruitenbeek; E L Theunissen; E Schneider; G Kauert Journal: Drug Alcohol Depend Date: 2006-05-24 Impact factor: 4.492
Authors: Wendy M Bosker; Kim P C Kuypers; Eef L Theunissen; Anke Surinx; Roos J Blankespoor; Gisela Skopp; Wayne K Jeffery; H Chip Walls; Cees J van Leeuwen; Johannes G Ramaekers Journal: Addiction Date: 2012-07-12 Impact factor: 6.526
Authors: S Jongen; A Vermeeren; N N J J M van der Sluiszen; M B Schumacher; E L Theunissen; K P C Kuypers; E F P M Vuurman; J G Ramaekers Journal: Psychopharmacology (Berl) Date: 2017-01-09 Impact factor: 4.530
Authors: Stefan Jongen; Nick N J J M van der Sluiszen; Dennis Brown; Eric F P M Vuurman Journal: Hum Psychopharmacol Date: 2018-05 Impact factor: 1.672
Authors: Edward Chesney; Dominic Oliver; Alastair Green; Simina Sovi; Jack Wilson; Amir Englund; Tom P Freeman; Philip McGuire Journal: Neuropsychopharmacology Date: 2020-04-08 Impact factor: 7.853
Authors: Ali Shahidi Zandi; Felix J E Comeau; Robert E Mann; Patricia Di Ciano; Eliyas P Arslan; Thomas Murphy; Bernard Le Foll; Christine M Wickens Journal: Cannabis Cannabinoid Res Date: 2021-08-24
Authors: Ashley Brooks-Russell; Tim Brown; Kyle Friedman; Julia Wrobel; John Schwarz; Gregory Dooley; Karen A Ryall; Benjamin Steinhart; Elise Amioka; Gary Milavetz; George Sam Wang; Michael J Kosnett Journal: Accid Anal Prev Date: 2021-08-14
Authors: Nadia R P W Hutten; T R Arkell; F Vinckenbosch; J Schepers; R C Kevin; E L Theunissen; K P C Kuypers; I S McGregor; J G Ramaekers Journal: Psychopharmacology (Berl) Date: 2022-10-13 Impact factor: 4.415
Authors: Caroline A MacCallum; Lindsay A Lo; Carly A Pistawka; April Christiansen; Michael Boivin; Melissa Snider-Adler Journal: Front Psychiatry Date: 2022-06-24 Impact factor: 5.435
Authors: Thomas R Arkell; Richard C Kevin; Frederick Vinckenbosch; Nicholas Lintzeris; Eef Theunissen; Johannes G Ramaekers; Iain S McGregor Journal: Addict Biol Date: 2021-12-22 Impact factor: 4.093